Hold Aurobindo Pharma; target of Rs 615: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

ICICI Direct's research report on Aurobindo Pharma

Aurobindo is a significant global generics player with 28 manufacturing facilities, including eight key formulations facilities in India and abroad along with three R&D centres. The current employee strength is more than 8000, which includes more than 750 scientists. FY22, API: formulations ratio was at 15:85. US formulations constitute 47% of revenues followed by Europe (28%), APIs (15%), RoW (6%) & ARV (4%) • Aurobindo is setting up a plant for production of Penicillin-G with capacity of 15,000 MT for Rs 1850 crore, under the PLI scheme.

Outlook

Maintain HOLD due to lack of ex-Injectable growth momentum till FY24. We also keep tab on margins in the backdrop of increased R&D. Valued at Rs 615 at 12x P/E on FY24E EPS of Rs 51.3.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Aurobindo Pharma - 120822 - ic